This was an observational cohort study using health registry/claims-style data, comparing pregnancy outcomes among people exposed to semaglutide before or during pregnancy versus those not exposed. The sample included pregnant patients who had filled prescriptions for semaglutide in the periconception or prenatal period and a much larger comparison group without semaglutide use. Researchers tracked outcomes such as gestational weight gain, fetal growth, preterm birth, pregnancy loss, and other adverse pregnancy events. Primary endpoints focused on whether semaglutide exposure was associated with higher rates of adverse maternal and neonatal outcomes.
Semaglutide exposure before or during pregnancy was associated with higher risks of several adverse outcomes compared with pregnancies without semaglutide use, including growth restriction and other complications. When comparing people who stopped semaglutide before pregnancy to those who stopped after pregnancy began, risks were similar, suggesting the risk signal was not strongly driven by direct in‑utero drug exposure. The authors propose that rebound weight gain or metabolic shifts after stopping semaglutide may contribute to the observed risks. Absolute risk increases appear modest but clinically relevant, and the study cannot fully exclude residual confounding (such as underlying obesity, diabetes, or other comorbidities).
This was an observational study, so it shows associations, not proof of cause and effect. People prescribed semaglutide often have obesity, insulin resistance, or diabetes, all of which independently raise pregnancy risk; even with adjustments, residual confounding is likely. Exposure was based on prescription data, not actual use or adherence, and the exact timing relative to conception and early placental development may be imprecise. Data on lifestyle, nutrition quality, weight‑loss speed, degree of rebound weight gain, and other medications were limited, which could influence outcomes. Results may not apply equally to all ages, body sizes, ethnic groups, or to other GLP‑1 drugs, and safety conclusions for intentional use in pregnancy cannot be drawn from this design. Patients should not change medications solely based on this study without individualized medical guidance.
This study adds to emerging data raising caution about GLP‑1 receptor agonist use in the periconception and pregnancy window. The finding that risks did not differ substantially between pre‑pregnancy and early‑pregnancy discontinuation supports the hypothesis that rapid metabolic changes, weight cycling, or underlying disease burden may be key drivers. Methodological strengths include use of real‑world data and comparison groups; limitations include confounding by indication (patients on semaglutide are typically higher‑risk to begin with), reliance on prescription fill data (not confirmed ingestion), and limited granularity on timing and dosing. Overall, this aligns with existing guidance to avoid GLP‑1 drugs in pregnancy, but it refines the concern from direct teratogenicity toward indirect effects from weight and metabolic instability; it does not prove that semaglutide itself causes these outcomes.
For patients planning pregnancy, semaglutide and similar GLP‑1 medications should generally be stopped well before trying to conceive, with a plan to stabilize weight and blood sugar afterward. Rapid weight loss followed by rebound gain around conception may stress hormones, ovulation, and placental development, so slower, sustainable strategies (nutrition, movement, sleep, inflammation control) are safer. Root‑cause workup for weight and metabolic issues—insulin resistance, thyroid, PCOS, gut health, sleep apnea, chronic inflammation—remains key, especially before stopping a GLP‑1 agent. Anyone who becomes pregnant while on semaglutide should not stop or continue on their own; they should urgently review options, timing, and monitoring with their obstetric and fertility clinicians.
This study looked at women who used the weight‑loss and diabetes medicine semaglutide around the time they became pregnant. Those who used it close to or during pregnancy had higher chances of pregnancy problems compared with women who did not use it, but the risk was similar whether they stopped before or after they were pregnant. This suggests the body’s rebound after stopping the drug—like rapid weight regain or blood‑sugar swings—may be part of the problem, not just the medicine being in the womb. If you are trying to conceive or are pregnant and using a GLP‑1 medicine, it’s important to talk with your clinician about safer timing, your weight and blood‑sugar patterns, and ways to support your hormones and cycles from the root causes rather than relying only on medication.
Consider GLP‑1 receptor agonist exposure as a marker for higher baseline metabolic and inflammatory risk; integrate this with preconception counseling and risk stratification. The lack of major differences between pre‑ and early‑pregnancy discontinuation implies that abrupt discontinuation with rapid weight or glycemic rebound around implantation/placentation may be problematic; aim for planned tapering and stabilization several months before conception where feasible. In restorative frameworks, pair GLP‑1 therapy (if used) with root‑cause workup: fasting insulin and glucose, HbA1c, HOMA‑IR, lipid panel, hs‑CRP, liver enzymes, thyroid panel (TSH, free T4, free T3, TPO), prolactin, androgens, 25‑OH vitamin D, and structured cycle charting (luteal phase adequacy, ovulation timing, cervical mucus quality). For patients conceiving after GLP‑1 use, consider closer monitoring of early fetal growth (serial ultrasounds), blood pressure, weight trajectory, and glucose tolerance, even in non‑diabetic patients. Current data support avoiding GLP‑1 agents in pregnancy and highlight the need to manage underlying obesity/IR with sustainable lifestyle, targeted supplements, and treatment of coexisting conditions (PCOS, sleep apnea, thyroid disease) to minimize weight cycling and metabolic volatility during the periconception period.
Educational insights, not a diagnosis or individualized treatment advice. Discuss findings with your own clinician. Visit Reproductive Health Insights to explore fertility resources.